Heart failure with preserved ejection fraction (HFpEF) can arise from cardiac and vascular remodeling processes following long-lasting hypertension. Efficacy of common HF therapeutics is unsatisfactory in HFpEF. Evidence suggests that stimulators of the nitric oxide–sensitive soluble guanylyl cyclase (NOsGC) could be of use here. We aimed to characterize the complex cardiovascular effects of NOsGC stimulation using NO-independent stimulator BAY 41-8543 in a double-transgenic rat (dTGR) model of HFpEF. We show a drastically improved survival rate of treated dTGR. We observed less cardiac fibrosis, macrophage infiltration, and gap junction remodeling in treated dTGR. Microarray analysis revealed that treatment of dTGR corrected the dysregulateion of cardiac genes associated with fibrosis, inflammation, apoptosis, oxidative stress, and ion channel function toward an expression profile similar to healthy controls. Treatment reduced systemic blood pressure levels and improved endothelium-dependent vasorelaxation of resistance vessels. Further comprehensive in vivo phenotyping showed an improved diastolic cardiac function, improved hemodynamics, and less susceptibility to ventricular arrhythmias. Short-term BAY 41-8543 application in isolated untreated transgenic hearts with structural remodeling significantly reduced the occurrence of ventricular arrhythmias, suggesting a direct nongenomic role of NOsGC stimulation on excitation. Thus, NOsGC stimulation was highly effective in improving several HFpEF facets in this animal model, underscoring its potential value for patients.
Nicola Wilck, Lajos Markó, András Balogh, Kristin Kräker, Florian Herse, Hendrik Bartolomaeus, István A. Szijártó, Maik Gollasch, Nadine Reichhart, Olaf Strauss, Arnd Heuser, Damian Brockschnieder, Axel Kretschmer, Ralf Lesche, Florian Sohler, Johannes-Peter Stasch, Peter Sandner, Friedrich C. Luft, Dominik N. Müller, Ralf Dechend, Nadine Haase
Title and authors | Publication | Year |
---|---|---|
Cyclic GMP and PKG Signaling in Heart Failure
G Numata, E Takimoto |
Frontiers in pharmacology | 2022 |
Single Donor Infusion of S-Nitroso-Human-Serum-Albumin Attenuates Cardiac Isograft Fibrosis and Preserves Myocardial Micro-RNA-126-3p in a Murine Heterotopic Heart Transplant Model
Anne-Kristin Schaefer, Attila Kiss, André Oszwald, Felix Nagel, Eylem Acar, Arezu Aliabadi-Zuckermann, Matthias Hackl, Andreas Zuckermann, Renate Kain, Andrzej Jakubowski, Peter Ferdinandy, Seth Hallström, Bruno K Podesser |
Transplant international : official journal of the European Society for Organ Transplantation | 2022 |
Endothelial Dysfunction in Heart Failure With Preserved Ejection Fraction: What are the Experimental Proofs?
Cornuault L, Rouault P, Duplàa C, Couffinhal T, Renault MA |
Frontiers in physiology | 2022 |
Nitric Oxide Signalling in Descending Vasa Recta after Hypoxia/Re-Oxygenation
Xu M, Lichtenberger FB, Erdoǧan C, Lai E, Persson PB, Patzak A, Khedkar PH |
International journal of molecular sciences | 2022 |
Bibliometric study of soluble guanylate cyclase stimulators in cardiovascular research based on web of science from 1992 to 2021
Jia XY, Liu YM, Wang YF, An JY, Peng KL, Wang H |
Frontiers in pharmacology | 2022 |
From Structural to Functional Hypertension Mediated Target Organ Damage—A Long Way to Heart Failure with Preserved Ejection Fraction
Mancusi C, Lembo M, Manzi MV, Basile C, Fucile I, Morisco C |
Journal of Clinical Medicine | 2022 |
Vascular dysfunction in HFpEF: Potential role in the development, maintenance, and progression of the disease
Saavedra-Alvarez A, Pereyra KV, Toledo C, Iturriaga R, Del Rio R |
Frontiers in Cardiovascular Medicine | 2022 |
New Opportunities in Heart Failure with Preserved Ejection Fraction: From Bench to Bedside… and Back.
Parra-Lucares A, Romero-Hernández E, Villa E, Weitz-Muñoz S, Vizcarra G, Reyes M, Vergara D, Bustamante S, Llancaqueo M, Toro L |
Biomedicines | 2022 |